Program Description
Target Audience
This activity is intended for rheumatologists and other specialists involved in the management of patients with systemic lupus erythematosus (SLE).
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Describe SLE pathophysiology with a focus on novel treatment targets
- Evaluate patients with SLE using consensus classification criteria, measures of disease activity, and clinical trial endpoints
- Discuss new clinical trial data and regulatory status for current and emerging targeted therapies in moderate-to-severe SLE
- Manage patients with SLE based on a treat-to-target approach, evolving clinical evidence, unresolved symptoms, and patient preferences
Statement of Need
Despite improved understanding of pathophysiologic mechanisms, development of classification criteria, and hope for more available treatments, specialists face challenges in managing the diverse manifestations of SLE. This live CME webinar program will be offered 3 times, once for each US region – the eastern/Atlantic region, the central/Midwest region, and the western/Pacific region. National and regional experts in SLE will share interpretive insights on SLE diagnosis, SLE pathogenesis, traditional treatment modalities, and recent clinical trial data for newer targeted therapies. The program will also look at how clinicians and patients define treatment success and will feature several faculty discussions addressing today’s clinical challenges in SLE treatment. This forward-looking CME program will offer insights and evolving evidence to help rheumatologists provide care that minimizes recurrent disease activity flares and cumulative organ damage, both key factors in long-term outcomes.